Geodon (ziprasidone) has been linked to diabetes and hyperglycemia. Geodon is used to treat patients with schizophrenia.

The FDA has asked Pfizer to add a new warning to the popular schizophrenia drug Geodon, which warns patients that Geodon can cause diabetes and other blood sugar disorders such as hyperglycemia. In a recent study, atypical antipychotics similar to Geodon were found to cause diabetes 50 percent more often than older drugs.

Several years ago, the FDA became concerned about the possibility that ziprasidone might increase the possibility of a specific, potentially fatal heart-rhythm irregularity called torsade de pointes. The FDA did not approve ziprasidone in 1998 because of those concerns.

Additional Geodon side effects include: feeling unusually tired, nausea, constipation, dizziness, restlessness, diarrhea, rash, cough and runny nose, and abnormal muscle movements, including tremor, shuffling, and uncontrollable movements.

Pfizer had petitioned to have the class warning dropped or modified for diabetes with regard to Geodon (Ziprasidone). The new Geodon package insert with a revised warning, and a pfizer dear doctor letter about the change, notes the problems associated with other atypical antipsychotics, but states that "it is not known if GEODON is associated with an increased risk of diabetes".

If you feel you qualify for damages or remedies that might be awarded in this class action please fill in the form to the right to submit your complaint.

If your injustice does not match the complaint described above, please use this form to register your complaint. Thank you.

Add Your Comment on This Issue

Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment: